{"id":25159,"date":"2024-11-21T12:03:16","date_gmt":"2024-11-21T11:03:16","guid":{"rendered":"https:\/\/idibell.cat\/es\/?page_id=25159"},"modified":"2024-11-21T15:47:46","modified_gmt":"2024-11-21T14:47:46","slug":"quimica-medica-y-diseno-de-farmacos","status":"publish","type":"page","link":"https:\/\/idibell.cat\/es\/investigacion\/area-de-cancer\/programa-de-mecanismos-moleculares-y-terapia-experimental-en-oncologia-oncobell\/quimica-medica-y-diseno-de-farmacos\/","title":{"rendered":"Qu\u00edmica M\u00e9dica y Dise\u00f1o de F\u00e1rmacos"},"content":{"rendered":"\n<h1>\n\t\tQu\u00edmica m\u00e9dica y dise\u00f1o de f\u00e1rmacos\n\t<\/h1>\n<h3>\n\t\tResumen\n\t<\/h3>\n\t<p>El grupo de investigaci\u00f3n en qu\u00edmica m\u00e9dica y dise\u00f1o de f\u00e1rmacos es un grupo computacional y experimental que utiliza herramientas de qu\u00edmica org\u00e1nica, biolog\u00eda, y ciencia de datos para entender mejor el mecanismo de acci\u00f3n de los f\u00e1rmacos para utilizarlos de forma m\u00e1s eficiente en medicina de precisi\u00f3n y dise\u00f1ar nuevos f\u00e1rmacos m\u00e1s seguros y eficaces para el tratamiento del c\u00e1ncer. El grupo tambi\u00e9n colabora activamente en iniciativas internacionales de ciencia abierta en qu\u00edmica biol\u00f3gica centradas en la recopilaci\u00f3n, estandarizaci\u00f3n y accesibilidad de Big Data. Por \u00faltimo, tambi\u00e9n desarrolla sus propias herramientas de inteligencia artificial para acelerar el descubrimiento de f\u00e1rmacos.<\/p>\n<> <\/>\n<h2>Publicaciones<\/h2>\n\t\t\t\t<img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/idibell.cat\/es\/wp-content\/uploads\/sites\/4\/2024\/11\/Medicinal-chemistry-drug-design.jpg\" alt=\"Medicinal-chemistry-&amp;-drug-design\" itemprop=\"image\" height=\"300\" width=\"600\" title=\"Medicinal-chemistry-&amp;-drug-design\" onerror=\"this.style.display='none'\"  \/>\n\t\t\t\t\t<a href=\"#\" id=\"fl-accordion--label-0\" tabindex=\"0\" aria-controls=\"fl-accordion--panel-0\">L\u00edneas estrat\u00e9gicas<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<a href=\"#\" id=\"fl-accordion--icon-0\" tabindex=\"0\" aria-controls=\"fl-accordion--panel-0\"><i>Expand<\/i><\/a>\n\t\t\t\t\t<ul>\n<li>Desarrollar recursos de biolog\u00eda qu\u00edmica de ciencia abierta.<\/li>\n<li>Aprovechar los efectos de los medicamentos a nivel de sistemas en medicina de precisi\u00f3n.<\/li>\n<li>Explotar Big Data e IA para descubrir medicamentos m\u00e1s eficaces<\/li>\n<\/ul>\n\t\t\t\t\t<a href=\"#\" id=\"fl-accordion--label-1\" tabindex=\"0\" aria-controls=\"fl-accordion--panel-1\">Publicaciones seleccionadas<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<a href=\"#\" id=\"fl-accordion--icon-1\" tabindex=\"0\" aria-controls=\"fl-accordion--panel-1\"><i>Expand<\/i><\/a>\n\t\t\t\t\t<ul>\n<li>Hu H, Serra C, Zhang W, Scrivo A, Fernandez-Carasa I, Consiglio A, Aytes A, Pujana MA, *Llebaria A, *Antolin AA. <strong>Identification of differential biological activity and synergy between the PARP inhibitor rucaparib and its major metabolite.<\/strong> Cell Chemical Biology, in press.<\/li>\n<li>di Micco,+ Antolin AA,+ Mitsopoulos C, Villasclaras Fernandez E, Mica IL, et al. <strong>canSAR: update to the cancer translational research and drug discovery knowledgebase<\/strong>. Nucleic Acids Res. 51, D1212-D1219 (2023).<\/li>\n<li>Antolin AA, Sanfelice D, Crisp A, Villasclaras Fernandez E, Mica IL, et al. <strong>The Chemical Probes Portal: an expert review based public resource to empower chemical probe assessment, selection and use<\/strong>. Nucleic Acids Res. 51, D1492-D1502 (2023).<\/li>\n<li>*Antolin AA, Clarke PA, Collins I, *Workman P, *Al-Lazikani B. <strong>Evolution of kinase polypharmacology across HSP90 drug discovery<\/strong>. Cell Chemical Biology. 28, 1-13 (2021).<\/li>\n<li>*Workman P, *Antolin AA, *Al-Lazikani B. <strong>Transforming cancer drug discovery with Big Data and AI<\/strong>. Expert Opin Drug Discov. 14, 1089-1095 (2019).<\/li>\n<\/ul>\n\t\t\t\t\t<a href=\"#\" id=\"fl-accordion--label-2\" tabindex=\"0\" aria-controls=\"fl-accordion--panel-2\">Proyectos seleccionados<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<a href=\"#\" id=\"fl-accordion--icon-2\" tabindex=\"0\" aria-controls=\"fl-accordion--panel-2\"><i>Expand<\/i><\/a>\n\t\t\t\t\t<ul>\n<li><strong>Systems-based Characterization of Drug Metabolites to Exploit them in Precision medicine<\/strong>. Agency: Spanish Ministry of Economy (MINECO) &#8211; Plan Nacional. IP: Dr. Albert Antolin. 2023-2026. Amount: 130.000 \u20ac.<\/li>\n<li><strong>Systems Drug Discovery to Tackle Cancer Drug Resistance<\/strong>. Agency: Instituto de Salud Carlos III (ISCIII) &#8211; Miguel Servet Fellowship. IP: Dr. Albert Antolin. 2023 &#8211; 2028. Amount: 240.000 \u20ac.<\/li>\n<li><strong>Rational development of KRAS inhibitors that simultaneously inhibit kinases<\/strong>. Agency: VIVAN Therapeutics (London, UK) &#8211; industrial collaboration. IP: Dr. Albert Antolin (coordinator), Prof. Paul Workman (ICR) and Dr. Nahuel Villegas (VIVAN). 2023 &#8211; June 2024. Amount: 50.000 \u00a3<\/li>\n<li><strong>Systems Drug Discovery to Tackle Cancer Drug Resistance<\/strong>. Agency: La Caixa Foundation. IP: Dr. Albert Antolin. 2022 &#8211; 2023. Amount: 300.000 \u20ac.<\/li>\n<\/ul>\n\t\t\t\t<img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/idibell.cat\/es\/wp-content\/uploads\/sites\/4\/2023\/01\/Albert-Antolin-Hernandez-150x150.jpg\" alt=\"Albert-Antolin-Hernandez\" itemprop=\"image\" height=\"150\" width=\"150\" title=\"Albert-Antolin-Hernandez\" onerror=\"this.style.display='none'\"  \/>\n<h4>\n\t\tAntolin Hernandez, Albert\n\t<\/h4>\n<h4>\n\t\t<a href=\"mailto:aantolin@idibell.cat\" title=\"aantolin@idibell.cat\" target=\"_blank\" rel=\"noopener\">\n\t\taantolin@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n<h2>\n\t\tInvestigadores principales\n\t<\/h2>\n\t\t\t\t<img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/idibell.cat\/es\/wp-content\/uploads\/sites\/4\/2023\/01\/Albert-Antolin-Hernandez-150x150.jpg\" alt=\"Albert-Antolin-Hernandez\" itemprop=\"image\" height=\"150\" width=\"150\" title=\"Albert-Antolin-Hernandez\" onerror=\"this.style.display='none'\"  \/>\n<h4>\n\t\tAntolin Hernandez, Albert\n\t<\/h4>\n<h4>\n\t\t<a href=\"mailto:aantolin@idibell.cat\" title=\"aantolin@idibell.cat\" target=\"_blank\" rel=\"noopener\">\n\t\taantolin@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n<h4>\n\t\tENLACES RELACIONADOS\n\t<\/h4>\n<h4>\n\t\t<a href=\"http:\/\/ico.gencat.cat\/ca\/recerca\/Programa-ProCURE\/\" title=\"ProCURE\" target=\"_blank\" rel=\"noopener\">\n\t\tProCURE\n\t\t<\/a>\n\t<\/h4>\n<h4>\n\t\t<a href=\"https:\/\/twitter.com\/ProcureICO\" title=\"@ProcureICO\" target=\"_blank\" rel=\"noopener\">\n\t\t@ProcureICO\n\t\t<\/a>\n\t<\/h4>\n<h2>\n\t\tEquipo\n\t<\/h2>\n\t\t\t\t\t\t\t\t<a href=\"#\" id=\"fl-tabs--label-0\" data-index=\"0\" aria-selected=\"true\" aria-controls=\"fl-tabs--panel-0\" aria-expanded=\"true\" role=\"tab\" tabindex=\"0\">\t\t\t\tJefes\/as de grupo\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t<a href=\"#\" id=\"fl-tabs--label-1\" data-index=\"1\" aria-selected=\"false\" aria-controls=\"fl-tabs--panel-1\" aria-expanded=\"false\" role=\"tab\" tabindex=\"0\">\t\t\t\tInvestigadores\/as postdoctorales\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t<a href=\"#\" id=\"fl-tabs--label-2\" data-index=\"2\" aria-selected=\"false\" aria-controls=\"fl-tabs--panel-2\" aria-expanded=\"false\" role=\"tab\" tabindex=\"0\">\t\t\t\tSoporte cient\u00edfico\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t<a href=\"#\" id=\"fl-tabs--label-3\" data-index=\"3\" aria-selected=\"false\" aria-controls=\"fl-tabs--panel-3\" aria-expanded=\"false\" role=\"tab\" tabindex=\"0\">\t\t\t\tEstudiantes\t\t\t\t<\/a>\n\t\t\t\t\t\tJefes\/as de grupo\n\t\t\t\t\t\t\t\t\t\t\t<ul>\n<li>Antolin Hernandez, Albert<\/li>\n<\/ul>\n\t\t\t\t\t\tInvestigadores\/as postdoctorales\n\t\t\t\t\t\t\t\t\t\t\t<ul>\n<li>Manen Freixa, Leticia<\/li>\n<\/ul>\n\t\t\t\t\t\tSoporte cient\u00edfico\n\t\t\t\t\t\t\t\t\t\t\t<ul>\n<li>Santos Gil, Santiago<\/li>\n<\/ul>\n\t\t\t\t\t\tEstudiantes\n\t\t\t\t\t\t\t\t\t\t\t<ul>\n<li>Ruvo, Luca<\/li>\n<\/ul>\n<h2>\n\t\tNoticias relacionadas\n\t<\/h2>\n\t<meta itemscope itemprop=\"mainEntityOfPage\" itemtype=\"https:\/\/schema.org\/WebPage\" itemid=\"http:\/\/24187\" content=\"La reutilizaci\u00f3n de medicamentos: nuevas oportunidades para los pacientes oncol\u00f3gicos\" \/><meta itemprop=\"datePublished\" content=\"2024-04-19\" \/><meta itemprop=\"dateModified\" content=\"2024-11-21\" \/><meta itemprop=\"name\" content=\"IDIBELL\"\/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/es\/wp-content\/uploads\/sites\/4\/2023\/03\/cropped-Marca-B.png\"\/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/es\/author\/comunicacio\/\" \/><meta itemprop=\"name\" content=\"comunicacio\" \/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/es\/wp-content\/uploads\/sites\/4\/2024\/04\/Albert-Antolin-Repurposing.jpg\" \/><meta itemprop=\"width\" content=\"1366\" \/><meta itemprop=\"height\" content=\"768\" \/><meta itemprop=\"interactionType\" content=\"https:\/\/schema.org\/CommentAction\" \/><meta itemprop=\"userInteractionCount\" content=\"0\" \/>\t\n\t\t\t\t<a href=\"https:\/\/idibell.cat\/es\/2024\/04\/la-reutilizacion-de-medicamentos-nuevas-oportunidades-para-los-pacientes-oncologicos\/\" title=\"La reutilizaci\u00f3n de medicamentos: nuevas oportunidades para los pacientes oncol\u00f3gicos\"><\/a>\n\t\t\t\t< itemprop=\"headline\">\n\t\t\t<a href=\"https:\/\/idibell.cat\/es\/2024\/04\/la-reutilizacion-de-medicamentos-nuevas-oportunidades-para-los-pacientes-oncologicos\/\" title=\"La reutilizaci\u00f3n de medicamentos: nuevas oportunidades para los pacientes oncol\u00f3gicos\">La reutilizaci\u00f3n de medicamentos: nuevas oportunidades para los pacientes oncol\u00f3gicos<\/a>\n\t\t<\/>\n\t\t\tBy <a href=\"https:\/\/idibell.cat\/es\/author\/comunicacio\/\">comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t  |  \n\t\t\t\t\t\t\t\t\t19\/04\/2024\t\t\t\t\t\t\t\n\t<meta itemscope itemprop=\"mainEntityOfPage\" itemtype=\"https:\/\/schema.org\/WebPage\" itemid=\"http:\/\/23823\" content=\"Un f\u00e1rmaco anticanceroso abre una nueva v\u00eda de tratamiento del Parkinson\" \/><meta itemprop=\"datePublished\" content=\"2024-02-09\" \/><meta itemprop=\"dateModified\" content=\"2024-11-21\" \/><meta itemprop=\"name\" content=\"IDIBELL\"\/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/es\/wp-content\/uploads\/sites\/4\/2023\/03\/cropped-Marca-B.png\"\/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/es\/author\/comunicacio\/\" \/><meta itemprop=\"name\" content=\"comunicacio\" \/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/es\/wp-content\/uploads\/sites\/4\/2024\/02\/Albert-Antolin.jpg\" \/><meta itemprop=\"width\" content=\"1366\" \/><meta itemprop=\"height\" content=\"768\" \/><meta itemprop=\"interactionType\" content=\"https:\/\/schema.org\/CommentAction\" \/><meta itemprop=\"userInteractionCount\" content=\"0\" \/>\t\n\t\t\t\t<a href=\"https:\/\/idibell.cat\/es\/2024\/02\/un-farmaco-anticanceroso-abre-una-nueva-via-de-tratamiento-del-parkinson\/\" title=\"Un f\u00e1rmaco anticanceroso abre una nueva v\u00eda de tratamiento del Parkinson\"><\/a>\n\t\t\t\t< itemprop=\"headline\">\n\t\t\t<a href=\"https:\/\/idibell.cat\/es\/2024\/02\/un-farmaco-anticanceroso-abre-una-nueva-via-de-tratamiento-del-parkinson\/\" title=\"Un f\u00e1rmaco anticanceroso abre una nueva v\u00eda de tratamiento del Parkinson\">Un f\u00e1rmaco anticanceroso abre una nueva v\u00eda de tratamiento del Parkinson<\/a>\n\t\t<\/>\n\t\t\tBy <a href=\"https:\/\/idibell.cat\/es\/author\/comunicacio\/\">comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t  |  \n\t\t\t\t\t\t\t\t\t09\/02\/2024\t\t\t\t\t\t\t\n\t<meta itemscope itemprop=\"mainEntityOfPage\" itemtype=\"https:\/\/schema.org\/WebPage\" itemid=\"http:\/\/23040\" content=\"Nuevo acuerdo de colaboraci\u00f3n con el ICR y Vivan Therapeutics para dise\u00f1ar nuevos tratamientos personalizados contra el c\u00e1ncer\" \/><meta itemprop=\"datePublished\" content=\"2023-07-13\" \/><meta itemprop=\"dateModified\" content=\"2024-11-21\" \/><meta itemprop=\"name\" content=\"IDIBELL\"\/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/es\/wp-content\/uploads\/sites\/4\/2023\/03\/cropped-Marca-B.png\"\/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/es\/author\/comunicacio\/\" \/><meta itemprop=\"name\" content=\"comunicacio\" \/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/es\/wp-content\/uploads\/sites\/4\/2023\/07\/NO062-A-Antolin_Vivan-Tx-Imatge-noti.jpg\" \/><meta itemprop=\"width\" content=\"1366\" \/><meta itemprop=\"height\" content=\"768\" \/><meta itemprop=\"interactionType\" content=\"https:\/\/schema.org\/CommentAction\" \/><meta itemprop=\"userInteractionCount\" content=\"0\" \/>\t\n\t\t\t\t<a href=\"https:\/\/idibell.cat\/es\/2023\/07\/nuevo-acuerdo-de-colaboracion-con-el-icr-y-vivan-therapeutics-para-disenar-nuevos-tratamientos-personalizados-contra-el-cancer\/\" title=\"Nuevo acuerdo de colaboraci\u00f3n con el ICR y Vivan Therapeutics para dise\u00f1ar nuevos tratamientos personalizados contra el c\u00e1ncer\"><\/a>\n\t\t\t\t< itemprop=\"headline\">\n\t\t\t<a href=\"https:\/\/idibell.cat\/es\/2023\/07\/nuevo-acuerdo-de-colaboracion-con-el-icr-y-vivan-therapeutics-para-disenar-nuevos-tratamientos-personalizados-contra-el-cancer\/\" title=\"Nuevo acuerdo de colaboraci\u00f3n con el ICR y Vivan Therapeutics para dise\u00f1ar nuevos tratamientos personalizados contra el c\u00e1ncer\">Nuevo acuerdo de colaboraci\u00f3n con el ICR y Vivan Therapeutics para dise\u00f1ar nuevos tratamientos personalizados contra el c\u00e1ncer<\/a>\n\t\t<\/>\n\t\t\tBy <a href=\"https:\/\/idibell.cat\/es\/author\/comunicacio\/\">comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t  |  \n\t\t\t\t\t\t\t\t\t13\/07\/2023\t\t\t\t\t\t\t\n\t<meta itemscope itemprop=\"mainEntityOfPage\" itemtype=\"https:\/\/schema.org\/WebPage\" itemid=\"http:\/\/22496\" content=\"Una ayuda de la Fundaci\u00f3n \"la Caixa\" permite a Albert Antol\u00edn instalar su investigaci\u00f3n en el IDIBELL\" \/><meta itemprop=\"datePublished\" content=\"2023-03-23\" \/><meta itemprop=\"dateModified\" content=\"2024-11-21\" \/><meta itemprop=\"name\" content=\"IDIBELL\"\/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/es\/wp-content\/uploads\/sites\/4\/2023\/03\/cropped-Marca-B.png\"\/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/es\/author\/comunicacio\/\" \/><meta itemprop=\"name\" content=\"comunicacio\" \/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/es\/wp-content\/uploads\/sites\/4\/2023\/03\/NO036-A-Antolin_La-Caixa-Imatge-noti.jpg\" \/><meta itemprop=\"width\" content=\"1366\" \/><meta itemprop=\"height\" content=\"768\" \/><meta itemprop=\"interactionType\" content=\"https:\/\/schema.org\/CommentAction\" \/><meta itemprop=\"userInteractionCount\" content=\"0\" \/>\t\n\t\t\t\t<a href=\"https:\/\/idibell.cat\/es\/2023\/03\/una-ayuda-de-la-fundacion-la-caixa-permite-a-albert-antolin-instalar-su-investigacion-en-el-idibell\/\" title=\"Una ayuda de la Fundaci\u00f3n \"la Caixa\" permite a Albert Antol\u00edn instalar su investigaci\u00f3n en el IDIBELL\"><\/a>\n\t\t\t\t< itemprop=\"headline\">\n\t\t\t<a href=\"https:\/\/idibell.cat\/es\/2023\/03\/una-ayuda-de-la-fundacion-la-caixa-permite-a-albert-antolin-instalar-su-investigacion-en-el-idibell\/\" title=\"Una ayuda de la Fundaci\u00f3n \"la Caixa\" permite a Albert Antol\u00edn instalar su investigaci\u00f3n en el IDIBELL\">Una ayuda de la Fundaci\u00f3n \u00abla Caixa\u00bb permite a Albert Antol\u00edn instalar su investigaci\u00f3n en el IDIBELL<\/a>\n\t\t<\/>\n\t\t\tBy <a href=\"https:\/\/idibell.cat\/es\/author\/comunicacio\/\">comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t  |  \n\t\t\t\t\t\t\t\t\t23\/03\/2023\t\t\t\t\t\t\t\n\t\t<!-- .pp-content-posts -->\n\n","protected":false},"excerpt":{"rendered":"<p>Qu\u00edmica m\u00e9dica y dise\u00f1o de f\u00e1rmacos Resumen El grupo de investigaci\u00f3n en qu\u00edmica m\u00e9dica y dise\u00f1o de f\u00e1rmacos es un grupo computacional y experimental que utiliza herramientas de qu\u00edmica org\u00e1nica, biolog\u00eda, y ciencia de datos para entender mejor el mecanismo de acci\u00f3n de los f\u00e1rmacos para utilizarlos de forma m\u00e1s eficiente en medicina de precisi\u00f3n [&hellip;]<\/p>\n","protected":false},"author":8,"featured_media":0,"parent":448,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"site-sidebar-layout":"no-sidebar","site-content-layout":"page-builder","ast-site-content-layout":"full-width-container","site-content-style":"unboxed","site-sidebar-style":"unboxed","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"disabled","ast-breadcrumbs-content":"","ast-featured-img":"disabled","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"set","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"class_list":["post-25159","page","type-page","status-publish","hentry"],"publishpress_future_action":{"enabled":false,"date":"2024-11-28 23:56:50","action":"change-status","newStatus":"draft","terms":[],"taxonomy":""},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/pages\/25159","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/comments?post=25159"}],"version-history":[{"count":11,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/pages\/25159\/revisions"}],"predecessor-version":[{"id":25178,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/pages\/25159\/revisions\/25178"}],"up":[{"embeddable":true,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/pages\/448"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/media?parent=25159"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}